Rakipovski G, Rolin B, Nhr J, Klewe I, Frederiksen KS, Augustin R, Hecksher-Srensen J, Ingvorsen C, Polex-Wolf J, Knudsen LB
We do not recommend taking this product while pregnant or nursing
7 A meta-analysis of outcomes data from completed cardiovascular outcome trials suggests that, apart from saxagliptin, DPP-4 inhibitors have a neutral effect on the risk of cardiovascular death, myocardial infarction, stroke and hospitalisation for heart failure
It aims to guide clinicians and researchers in optimizing LCs benefits while addressing its long term cardiovascular safety concerns
thch Minh Tr mua ti rocy.vn c xp hng 5 5 sao Mi nhn hng, cm nhn ban u l ok